Corcept Pads Coffers with $30M Synthetic Royalty Deal
By Marie Powers
Thursday, August 9, 2012
Fresh from a public offering that raised $46 million in working capital, Corcept Therapeutics Inc. sold a synthetic capped royalty on future sales of Korlym (mifepristone) and its next-generation GR-II antagonists to BioPharma Secured Debt Fund II, an investment fund managed by Pharmakon Advisors.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.